Goodwill and Intangible Assets (Summary of Intangible Assets) (Details) $ in Thousands	1 Months Ended				3 Months Ended		12 Months Ended
	Feb. 28, 2017 USD ($) item	Aug. 31, 2016 USD ($) item	Mar. 31, 2016 USD ($) item	Jan. 31, 2016 USD ($)	Mar. 31, 2017 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Definite-lived intangible assets
Weighted-Average Life (Years)					12 years		12 years
Finite-Lived Intangible Assets, Gross					$ 38,774		$ 43,173
Accumulated Amortization					26,037		26,067
Finite-Lived Intangible Assets, Net					12,737		17,106
Indefinite-lived intangible assets
Goodwill recognized					4,031		3,976	$ 3,726
Subtotal, Original Cost					33,256		33,201
Subtotal, Net Book Value					33,256		33,201
Balance, Original Cost					72,030		76,374
Balance, Net Book Value					45,993		50,307
Payment to Acquire Business, Gross				$ 800		$ 4,761
Proceeds received from sale of ANDAs					1,000
Hikma Pharmaceuticals PLC
Indefinite-lived intangible assets
Number of Injectable Products Sold | item	14
Sale price of intangible assets	$ 6,400
Remaining Amount to be Paid Upon Completion of Certain Milestones	$ 5,400
Number of Days Upon Which Remainder of Payment is Due after Milestone Date	30 days
Royalty Fee Percentage	2.00%
Indemnification Liability Payable	$ 600
Gain recognized within operating (income) expenses					2,600
Finished Pharmaceutical Products
Indefinite-lived intangible assets
Goodwill recognized					4,031		3,976
Trademarks
Indefinite-lived intangible assets
Indefinite-lived intangible assets					$ 29,225		$ 29,225
Product rights
Definite-lived intangible assets
Weighted-Average Life (Years)					12 years		12 years
Finite-Lived Intangible Assets, Gross					$ 27,134		$ 27,134
Accumulated Amortization					24,906		24,461
Finite-Lived Intangible Assets, Net					$ 2,228		$ 2,673
Patents
Definite-lived intangible assets
Weighted-Average Life (Years)					10 years		10 years
Finite-Lived Intangible Assets, Gross					$ 293		$ 293
Accumulated Amortization					144		137
Finite-Lived Intangible Assets, Net					$ 149		$ 156
Land-use rights
Definite-lived intangible assets
Weighted-Average Life (Years)					39 years		39 years
Finite-Lived Intangible Assets, Gross					$ 2,540		$ 2,540
Accumulated Amortization					370		354
Finite-Lived Intangible Assets, Net					$ 2,170		$ 2,186
Other intangible assets
Definite-lived intangible assets
Weighted-Average Life (Years)					4 years		1 year
Finite-Lived Intangible Assets, Gross					$ 69		$ 574
Accumulated Amortization					34		534
Finite-Lived Intangible Assets, Net					$ 35		$ 40
International Medication Systems (UK) Limited
Definite-lived intangible assets
Weighted-Average Life (Years)		10 years
Indefinite-lived intangible assets
Payment to Acquire Business, Gross		$ 7,700
Marketing authorizations acquired		$ 9,200
Number of Different Injectable Chemical Entities | item		11
International Medication Systems (UK) Limited | Acquired international product rights
Definite-lived intangible assets
Weighted-Average Life (Years)					10 years		10 years
Finite-Lived Intangible Assets, Gross					$ 8,738		$ 8,632
Accumulated Amortization					583		359
Finite-Lived Intangible Assets, Net					$ 8,155		$ 8,273
Hikma Pharmaceuticals PLC
Definite-lived intangible assets
Weighted-Average Life (Years)			15 years
Indefinite-lived intangible assets
Payment to Acquire Business, Gross			$ 4,000
Number of Injectable Products Acquired | item			14
Number of Different Injectable Chemical Entities | item			11
Hikma Pharmaceuticals PLC | Acquired ANDAs
Definite-lived intangible assets
Weighted-Average Life (Years)							15 years
Finite-Lived Intangible Assets, Gross							$ 4,000
Accumulated Amortization							222
Finite-Lived Intangible Assets, Net							$ 3,778